

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Zylox-Tonbridge Medical Technology Co., Ltd.**

### **歸創通橋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2190)**

## **GRANT OF AWARDS PURSUANT TO THE SHARE AWARD SCHEME**

References are made to the announcements (the “**Announcements**”) dated November 6, 2024 and December 19, 2024, the circular (the “**Circular**”) dated December 3, 2024 of Zylox-Tonbridge Medical Technology Co., Ltd. (the “**Company**”), in relation to, among others, the adoption of the Share Award Scheme. Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements and the Circular.

On July 15, 2025, the Company granted a total of 250,000 Awards to one Service Provider (being the provider of consultancy service in connection with the research, development, production of the Company’s products, as defined under Rule 17.03A of the Listing Rules) (the “**Grant**”). Details of the Grant are set out as below:

Date of grant (“ <b>Grant Date</b> ”)	July 15, 2025
Grantee	one Service Provider, being an independent third party of the Group
Number of H Shares underlying the Awards	250,000 Awards
Purchase price	RMB2.1301 per H Share
Closing price of the H Shares on the Grant Date	HK\$20.25 per Share

Vesting period of the Awards	All Awards granted shall be vested on July 15, 2026.
Performance targets	Performance targets include (i) the financial results of the Company and/or the Group; (ii) executed material contracts of the Company and/or the Group; and (iii) the achievement of key milestones in the Company and/or the Group's business or product development.
Clawback mechanism	The Awards granted will be subject to the clawback mechanism as set out in the Share Award Schemes and grant letter of Awards as determined by the Board, including the cancellation of Awards at the discretion of the Board.

### **Reasons for and Benefits of the Grants**

The Board believes that the Grant serve to recognize the contribution of the Service Provider and motivate the Service Provider to continue contributing to the long term growth of the business of the Group and is appropriate to enhance the long term relationship with the Service Provider by aligning his interests with that of the Company and Shareholders. Therefore, it is of the view of the Board that the Grant is in line with the purposes of the Share Award Scheme.

To the best knowledge, information and belief of the Directors, having made all reasonable enquiries, (i) no financial assistance has been provided by the Group to the grantee under the Grant for the acceptance of Awards or purchase of Awards under the Share Award Scheme; (ii) the grantee under the Grant is not a Director, chief executive or substantial shareholder of the Company or an associate (as defined under the Listing Rules) of any of them; (iii) the grantee under the Grant is not a Related Entity Participant or a Service Provider Participant of whom the total number of options and awards granted and to be granted thereto in any 12-month period exceeds 0.1% of the H Shares in issue (excluding treasury shares of the Company); and (iv) the grantee under the Grant is not a participant with options and awards granted and to be granted exceeding the 1% individual limit under the Listing Rules.

Subsequent to the Grants, the number of H Shares available for future grants pursuant to the Share Awards Scheme shall be 611,939, among which, the number of H Shares available for future grant under the Service Provider Sublimit of the Share Award Scheme is 611,939.

By order of the Board  
**Zylox-Tonbridge Medical Technology Co., Ltd.**  
**Dr. Jonathon Zhong Zhao**  
*Chairman and Executive Director*

Hong Kong, July 15, 2025

*As of the date of this announcement, the Board comprises Dr. Jonathon Zhong Zhao, Mr. Yang Xie and Dr. Zheng Li as executive Directors, Dr. Steven Dasong Wang and Mr. Dongfang Li as non-executive Directors, and Dr. Jian Ji, Ms. Yun Qiu and Dr. Xiang Qian as independent non-executive Directors.*